Targeting Treatment of Soft Tissue Sarcomas

1. Front Matter

   Pages i-vi

   PDF

2. Targeted therapy: Ready for prime time?

   • Caroline Seynaeve, Jaap Verweij

   Pages 1-15

3. Volume-based radiotherapy targeting in soft tissue sarcoma

   • Iain Ward, Tara Haycocks, Michael Sharpe, Anthony Griffin, Charles Catton, David Jaffray et al.

   Pages 17-42

4. Preoperative therapy for soft tissue sarcoma

   • Janice N. Cormier, Howard N. Langstein, Peter W. T. Pisters

   Pages 43-63

5. TNF-based isolated limb perfusion: A decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas

   • Dirk J Grünhagen, Flavia Brunstein, Timo L.M. ten Hagen, Albertus N. van Geel, Johannes H.W. de Wilt, Alexander M.M. Eggermont

   Pages 65-79

6. Pitfalls in pathology of soft tissue sarcomas

   • Judith V.M.G. Bovée, Pancras C.W. Hogendoorn

   Pages 81-97

7. Molecular biology and cytogenetics of soft tissue sarcomas: Relevance for targeted therapies

   • Jonathan A. Fletcher

   Pages 99-116

8. KIT and PDGF as targets

   • Jaap Verweij

   Pages 117-127

9. Targeting mutant kinases in Gastrointestinal Stromal Tumors: A paradigm for molecular therapy of other sarcomas

   • Michael C. Heinrich, Christopher L. Corless

   Pages 129-150

10. Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-γ in liposarcomas

    • Jean-Yves Blay, Isabelle Ray-Coquard, Laurent Alberti, Dominique Ranchère

    Pages 151-167

11. Angiogenesis: a potential target for therapy of soft tissue sarcomas

    • K. Hoekman, H. M. Pinedo

    Pages 169-180

12. Back Matter

    Pages 181-184

    PDF

Recent achievements in the development of new techniques and agents for the treatment of cancer in general as well as for soft tissue sarcomas are tremendous. Molecular biology research has changed the landscape considerably and an increasing number of subtypes of soft tissue sarcomas are related to changes in cellular growth factors in the cell signaling pathways. This enables the development of targeted agents with specific activity against these factors. The presence of the KIT receptor at the surface of the gastrointestinal stroma tumor cell, and the activation constituted by mutations has led to the discovery of an extremely active specific KIT tyrosine kinase inhibitor.

In accordance with the more targeted approach in drug use, the changes in the field of radiation therapy and surgery basically focus on a better targeting of the disease, albeit not yet based on the molecular characteristics. All of these stress the importance of the multidisciplinary approach to the treatment of soft tissue sarcoma that was the focus of previous editions of this book.

Targeting Treatment of Soft Tissue Sarcomas summarizes the recent events in this field, putting the achievements in perspective. Physicians and researchers working in the field of soft tissue sarcomas must be aware of the changes in treatment, the underlying concepts, and of the changes we face in the future.

• TNF
• angiogenesis
• cell
• cytogenetics
• genetics
• molecular biology
• pathology
• radiotherapy
• surgery
• targeted therapy
• tumor

"The management of soft tissue sarcomas remains a difficult challenge. However, significant advances have occurred in our understanding of the important signaling molecules in these diseases. Experts in the field discuss the critical therapeutic targets and relevant treatment strategies for these malignancies."
(Steven T. Rosen, M.D., Series Editor)

• Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands

  Jaap Verweij

• Department of Medical Oncology, Free University Medical Center, Amsterdam, The Netherlands

  Herbert M. Pinedo

Policies and ethics